CJC-1295 No DAC (S2)

CJC-1295 without DAC (Modified GRF 1-29)

A short-acting GHRH analog that produces physiological GH pulses when combined with a GHRP like Ipamorelin.

Prohibited in competition. This compound is on the WADA Prohibited List (class [S0 / S2.3 / S2]), banned at all times, both in and out of competition. Athletes subject to WADA or USADA testing should not use it.

100% 50% · t½ ≈ 30m 25% 0m 30m 60m 90m 120m Serum level Time →
Molecular Weight 3367.9 Da
Half-Life ~30 minutes
Typical Dose 100–200 mcg
Cycle Length 8–16 weeks

Description

CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). The No DAC designation refers to the absence of a Drug Affinity Complex — a lysine-maleimide modification that, in the DAC version, allows the peptide to bind to albumin and dramatically extends its half-life. Without DAC, CJC-1295 has a half-life of approximately 30 minutes, closely mimicking the pulsatile nature of endogenous GHRH secretion. This physiological pulsatility is considered advantageous because it preserves the natural GH secretion pattern, reducing the risk of pituitary desensitization. It is almost universally combined with a GHRP such as Ipamorelin to achieve synergistic GH release through complementary receptor pathways.

Key Characteristics

Molecular Formula

C152H252N44O42

Molecular Weight

3367.9 Da

Half-Life

~30 minutes

Administration Routes

Subcutaneous injection

Typical Dose

100–200 mcg

Frequency

2–3x daily (with Ipamorelin)

Investigated Benefits

* Benefits based on preclinical/animal research unless otherwise noted.

Mechanism of Action

“A short-acting GHRH analog that produces physiological GH pulses when combined with a GHRP like Ipamorelin.”

CJC-1295 No DAC binds to and activates GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland. GHRHR is a Gs protein-coupled receptor; its activation stimulates adenylyl cyclase, elevating intracellular cAMP, which activates protein kinase A (PKA) and ultimately drives GH synthesis and secretion. The short half-life ensures that pituitary stimulation occurs in discrete pulses rather than continuously, which is important because continuous GHRH stimulation leads to receptor downregulation and blunted GH response. When combined with Ipamorelin (a ghrelin receptor agonist), the two peptides act on different receptor systems — GHRHR and GHSR-1a respectively — producing a synergistic GH pulse that is 2–10 times greater than either agent alone. This combination also suppresses somatostatin (the endogenous GH inhibitor) through ghrelin receptor signaling, further amplifying the GH response.

Administration Routes

Subcutaneous injection

Dosing Protocol

Typical Dose

100–200 mcg

Frequency

2–3x daily (with Ipamorelin)

Cycle Length

8–16 weeks

Administration

Subcutaneous injection

Protocol Notes

Always combine with Ipamorelin for synergistic GH release. Administer on empty stomach. Bedtime dose is most important. Inject CJC-1295 No DAC and Ipamorelin simultaneously or within minutes of each other.

Reconstitution Guide

Add 2 mL bacteriostatic water to 2 mg vial → 1000 mcg/mL For 100 mcg dose: draw 0.1 mL (10 units on U-100 syringe)

Storage Information

Lyophilized: refrigerate. Reconstituted: refrigerate and use within 30 days.

Quality & Sourcing Standards

When sourcing CJC-1295 No DAC for research purposes, the following quality benchmarks should be verified before use.

Purity:

>98% (verified by HPLC)

Certificate of Analysis (COA):

Must be provided by supplier

Endotoxin Testing:

<0.1 EU/mg (prevents bacterial contamination)

GMP Compliance:

Manufactured in cGMP-certified facility

Third-Party Testing:

Independent lab verification preferred

Storage Information

Lyophilized: refrigerate. Reconstituted: refrigerate and use within 30 days.

FDA Disclaimer

The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.

Research Highlights

1

Demonstrated GH and IGF-1 elevation in human studies

2

More physiological pulsatility than DAC version

3

Synergistic effect with GHRPs well-documented

Evidence Level

Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited.

Compatible Peptides

Peptides commonly used alongside CJC-1295 No DAC for synergistic effects.

BPC-157

A synthetic pentadecapeptide derived from gastric juice with extraordinary tissue healing properties across multiple organ systems.

Ipamorelin

The most selective GHRP available, stimulating GH release with minimal cortisol or prolactin elevation.

TB-500

A synthetic analog of Thymosin Beta-4 that promotes systemic healing through actin regulation and angiogenesis.

Protocols Featuring CJC-1295 No DAC

GH Optimization Protocol

Growth hormone optimization for body composition and recovery

Complete Recovery Stack

Comprehensive recovery from surgery or major injury

Quick Reference

Category

Hormone & GH

Status

Research Only
 

Dose

100–200 mcg

Frequency

2–3x daily (with Ipamorelin)

Cycle

8–16 weeks